Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
All Things Mobile Analytic Inc
American Leisure Holdings Inc
Axis Capital Holdings Limited Common Stock
Blackwolf Copper & Gold Ltd
Bragg Gaming Group Inc
CNS Pharmaceuticals, Inc. - Common Stock
Cassava Sciences, Inc. - Common Stock
Curaleaf Hldgs Inc
FG Imperii Acquisition Corp. - Class A Ordinary Shares
GDL Fund, The Common Shares of Beneficial Interest
Legend Power Sys Inc
Liquid Avatar Technologies Inc
Merit Medical Systems, Inc. - Common Stock
Mitsui Kinzoku ADR
Portfolio Building Block Integrated Oil and Gas and Exploration and Production
Ppx Mining Corp
Pudo Inc
REX FANG & Innovation Equity Premium Income ETF
Snowline Gold Corp
TMX Group Ltd
U.S. Bancorp
Viveve Medical, Inc. - Common Stock
X4 Pharmaceuticals, Inc. - Common Stock
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
5.920
-0.220 (-3.58%)
Delayed Quote
Updated: 3:50 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
October 27, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
October 12, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
October 08, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
October 07, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
September 23, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
September 17, 2026
VANCOUVER, BC September 17, 2026 - TheNewswire— StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract delivery...
Via
TheNewswire.com
Topics
Intellectual Property
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
September 17, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
September 11, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
September 08, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
September 04, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
September 01, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
August 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
August 11, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
August 06, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
August 03, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
July 30, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
July 28, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
July 20, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
July 17, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
July 16, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
July 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
July 10, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
July 07, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
June 29, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
June 22, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
June 18, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
June 16, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
June 05, 2026
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare
June 03, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Energy
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
